Nexalis Therapeutics (ASX:NX1) Common Stock: A$15.15 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nexalis Therapeutics Common Stock?

Nexalis Therapeutics ASX:NX1 Common Stock is A$15.15 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Nexalis Therapeutics's quarterly common stock stayed the same from Dec. 2024 (A$14.53 Mil) to Jun. 2025 (A$14.53 Mil) but then increased from Jun. 2025 (A$14.53 Mil) to Dec. 2025 (A$15.15 Mil).

Nexalis Therapeutics's annual common stock increased from Dec. 2023 (A$14.08 Mil) to Dec. 2024 (A$14.53 Mil) and increased from Dec. 2024 (A$14.53 Mil) to Dec. 2025 (A$15.15 Mil).

Nexalis Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Nexalis Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexalis Therapeutics Common Stock Chart

Nexalis Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.90 13.93 14.08 14.53 15.15

Nexalis Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.08 14.08 14.53 14.53 15.15

Nexalis Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$15.15 Mil mean?
Nexalis Therapeutics (ASX:NX1) has a Common Stock of A$15.15 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Nexalis Therapeutics and its competitors.
Is Nexalis Therapeutics' Common Stock too high?
Nexalis Therapeutics' current Common Stock is A$15.15 Mil.
How does Nexalis Therapeutics' Common Stock compare to VRTX and REGN?
Nexalis Therapeutics' Common Stock of A$15.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Nexalis Therapeutics and its competitors. Nexalis Therapeutics's current Common Stock is A$15.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalis Therapeutics stock overvalued right now?
Nexalis Therapeutics (ASX:NX1) has a current Common Stock of A$15.15 Mil. The current Common Stock is A$15.15 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Nexalis Therapeutics (ASX:NX1), the current Common Stock is A$15.15 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexalis Therapeutics Business Description

Address 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.